Le Lézard
Classified in: Health, Science and technology
Subject: Stock Sale/Buyback

ImmunoGen Announces Pricing of Public Offering of Common Stock


ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the pricing of an underwritten public offering of 21,325,000 shares of its common stock at a price of $4.25 per share, before underwriting discounts. ImmunoGen also granted the underwriters a 30-day option to purchase up to an additional 3,198,750 shares of its common stock at the public offering price, less the underwriting discounts. All of the shares of common stock in the offering are to be sold by ImmunoGen.

ImmunoGen anticipates the total gross proceeds from the offering (before deducting the underwriting discounts and estimated offering expenses) will be $90.6 million, excluding any exercise of the underwriters' option to purchase additional shares.

ImmunoGen intends to use the net proceeds of the offering, together with its existing capital, to fund its operations, including, but not limited to, clinical trial activities, supply of drug substance and drug product, pre-commercialization activities, capital expenditures, and working capital.

Jefferies, Cowen and William Blair are acting as joint book-running managers for the proposed offering.

The offering is expected to close on or about January 27, 2020, subject to satisfaction of customary closing conditions.

The securities described above are being offered by ImmunoGen pursuant to a shelf registration statement that was previously filed with the Securities and Exchange Commission (SEC) and became effective upon filing. This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. A preliminary prospectus supplement and accompanying prospectus relating to the offering was filed with the SEC and is available on the SEC's website at www.sec.gov. Copies of the final prospectus supplement may be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by e-mail at [email protected] or by telephone at (877) 821-7388; Cowen and Company, LLC c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY,11717, Attn: Prospectus Department, by email at [email protected] or by telephone at (833) 297-2926; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by e-mail at [email protected] or by telephone at (800) 621-0687.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to "target a better now."

This press release includes forward-looking statements, including statements related to the public offering of securities by ImmunoGen, including statements about the completion and timing of the public offering, the anticipated total gross proceeds from the offering and the intended use of the net proceeds of the offering and existing capital. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Various factors could cause actual results to differ materially from those discussed or implied in the forward-looking statements, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this release. Factors that could cause future results to differ materially from such expectations include, but are not limited to: uncertainties inherent in the initiation of future clinical trials and such other factors more fully described in ImmunoGen's Annual Report on Form 10-K for the year ended December 31, 2018 and other reports filed with the Securities and Exchange Commission.

95046004v.4


These press releases may also interest you

at 18:35
McorpCX, a leading customer and employee experience consultancy, and CX capabilities builder driving greater customer centricity since its founding in 2002, today announced the acquisition of UK-based myCXvision, a customer experience management...

at 18:30
The "Digital Banking - Global Strategic Business Report" has been added to  ResearchAndMarkets.com's offering. The global market for Digital Banking estimated at US$21.1 Billion in the year 2023, is projected to reach a revised size of US$53.5...

at 18:18
NASA is awarding approximately $3.7 million to 17 museums, science centers, and other informal education institutions as part of an initiative to ignite STEM excitement. The money will go toward projects that inspire students and their learning...

at 18:15
Epiq, a global technology-enabled leader to the legal industry and corporations, announced today Epiq Facilitatortm the premier, reliable, secure application for retrieving information, managing legal analysis, and administering voluntary...

at 18:15
The "Industrial Ovens - Global Strategic Business Report" has been added to  ResearchAndMarkets.com's offering. The global market for Industrial Ovens estimated at US$10.8 Billion in the year 2023, is projected to reach a revised size of US$14.8...

at 18:15
The acquisition solidifies ValeU Group as one of the premier firms in the nation offering Fortune 500 companies and smaller...



News published on and distributed by: